<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261079</url>
  </required_header>
  <id_info>
    <org_study_id>M016455_4125</org_study_id>
    <nct_id>NCT00261079</nct_id>
  </id_info>
  <brief_title>Fexofenadine in Pruritic Skin Disease</brief_title>
  <official_title>The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Handok Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Handok Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

        -  To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus
           prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin
           disease

      Secondary objective:

        -  To evaluate patient's satisfaction of Allegra treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of physician's assessment on pruritic score before and after 7-day treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient visual analogue scale change and Overall satisfaction.</measure>
  </secondary_outcome>
  <enrollment type="Actual">435</enrollment>
  <condition>Pruritus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The following information on clinical trials is provided for information purposes only to
        allow patients and physicians to have an initial discussion about the trial. This
        information is not intended to be complete information about the trial, to contain all
        considerations that may be relevant to potential participation in the trial, or to replace
        the advice of a personal physician or health professional.

        Main criteria are listed hereafter:

        Inclusion Criteria:

          -  All patients diagnosed with atopic dermatitis, contact dermatitis

        Exclusion Criteria:

          -  Other skin disease except atopic dermatitis, contact dermatitis.

          -  Subjects taken steroid within 4 weeks and antihistamine within 1 week before screening
             day.

          -  Pruritus localized only head and face

          -  Subjects with severe hepatic, renal, heart dysfunction.

          -  Subjects with history of alcohol and drug abuse.

          -  Pregnant and lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyou-Young Rhim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Handok Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Handok</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2005</study_first_submitted>
  <study_first_submitted_qc>December 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2005</study_first_posted>
  <last_update_submitted>November 5, 2007</last_update_submitted>
  <last_update_submitted_qc>November 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

